Get started
Author

Joseph D. Rager

Observed name: Joseph Rager
ORCID: 0009-0004-6008-9630
Observed ORCID: 0009-0004-6008-9630
OpenAlex ID: A5004443645
Evaluation of the MDR-MDCK cell line as a permeability screen for the blood–brain barrier
2004 · Qing Wang, Joseph D. Rager, et al. · International Journal of Pharmaceutics · 361
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
2023 · Jack Carter, Michael Hulse, et al. · Cancer Research Communications · 43
PDF
Cryopreserved Human Hepatocytes as Alternative in Vitro Model for Cytochrome P450 Induction Studies
2003 · Martha Garcia, Joseph Rager, et al. · In Vitro Cellular & Developmental Biology - Animal · 34
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers
2025 · Michael Hulse, Min Wang, et al. · Cancer Research · 31
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
2025 · Jan Philipp Bewersdorf, Xiaoli Mi, et al. · Leukemia · 21
PDF
Abstract 3263: Preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader
2022 · Michael Hulse, Anjana Agarwal, et al. · Cancer Research · 11
Abstract 1137: PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells
2021 · Koichi Ito, Venkat Thodima, et al. · Cancer Research · 8
Abstract 1138: PRMT5 inhibition downregulates MYB and NOTCH1 signaling, key molecular drivers of adenoid cystic carcinoma
2021 · Jack Carter, Koichi Ito, et al. · Cancer Research · 6
Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2
2024 · Artem Shvartsbart, Koichi Ito, et al. · Cancer Research · 4
Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers
2023 · Koichi Ito, Michael Hulse, et al. · Molecular Cancer Therapeutics · 4
Abstract 2159: PRMT5 inhibitor PRT543 displays potent antitumor activity in U2AF1S34F and RBM10LOF spliceosome-mutant non-small cell lung cancer in vitro and in vivo
2022 · Jack Carter, Koichi Ito, et al. · Cancer Research · 3
Abstract 5793: First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile
2026 · Monisha Sivakumar, Sarah Pawley, et al. · Cancer Research · 2
Abstract 1646: Elucidating the molecular mechanism of action of the first in human SMARCA2 selective degrader PRT3789
2025 · Min Wang, Miles Cowart, et al. · Cancer Research · 2
Abstract 1649: Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models
2025 · Monisha Sivakumar, Sarah Pawley, et al. · Cancer Research · 2
Exposure assessment of laboratory workers to hazardous waste from mice treated with tamoxifen and bromodeoxyuridine
2018 · Nancy L. Wayne, Sandra Duarte-Vogel, et al. · ACS Chemical Health & Safety · 2
In Vitro Hydrolysis of Latanoprost by Human Ocular Tissues
2012 · Fany L. Guerra, Joseph Rager, et al. · Investigative Ophthalmology & Visual Science · 2
Abstract C013: Clinical biomarkers based on PK/PD modeling to guide the development for a first-in-class, highly selective SMARCA2 (BRM) degrader, PRT3789
2023 · Min Wang, Andrew Moore, et al. · Molecular Cancer Therapeutics · 1
Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer
2023 · Yue Zou, Srijita Dhar, et al. · Cancer Research · 1
Discovery of Tetrasubstituted Quinazolin-4(3 H )-ones as Wild-type-sparing, Highly Selective PI3KαH1047R Inhibitors
2026 · Chun Chen, Ryan Holmes, et al. · Journal of Medicinal Chemistry
Figure S10 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026 · Michael Hulse, Min Wang, et al.
Figure S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026 · Michael Hulse, Min Wang, et al.
Figure S2 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026 · Michael Hulse, Min Wang, et al.
Table S4 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026 · Michael Hulse, Min Wang, et al.
Table S6 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026 · Michael Hulse, Min Wang, et al.
Figure S1 from PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2026 · Michael Hulse, Min Wang, et al.
Works count: 63
Citation count: 533
H-index: 7
I10-index: 6
Year
Topic
Type